- Home
- SIDU vs NRXP Comparison
SIDU vs NRXP Comparison
Compare SIDU & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIDU
- NRXP
- Stock Information
- Founded
- SIDU 2012
- NRXP 2015
- Country
- SIDU United States
- NRXP United States
- Employees
- SIDU N/A
- NRXP N/A
- Industry
- SIDU Telecommunications Equipment
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SIDU Telecommunications
- NRXP Health Care
- Exchange
- SIDU Nasdaq
- NRXP Nasdaq
- Market Cap
- SIDU 30.0M
- NRXP 58.5M
- IPO Year
- SIDU 2021
- NRXP N/A
- Fundamental
- Price
- SIDU $1.19
- NRXP $2.83
- Analyst Decision
- SIDU
- NRXP Strong Buy
- Analyst Count
- SIDU 0
- NRXP 4
- Target Price
- SIDU N/A
- NRXP $28.50
- AVG Volume (30 Days)
- SIDU 1.5M
- NRXP 137.7K
- Earning Date
- SIDU 08-18-2025
- NRXP 08-13-2025
- Dividend Yield
- SIDU N/A
- NRXP N/A
- EPS Growth
- SIDU N/A
- NRXP N/A
- EPS
- SIDU N/A
- NRXP N/A
- Revenue
- SIDU $3,860,985.00
- NRXP N/A
- Revenue This Year
- SIDU $144.49
- NRXP N/A
- Revenue Next Year
- SIDU N/A
- NRXP $230.95
- P/E Ratio
- SIDU N/A
- NRXP N/A
- Revenue Growth
- SIDU N/A
- NRXP N/A
- 52 Week Low
- SIDU $1.08
- NRXP $1.10
- 52 Week High
- SIDU $7.65
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SIDU 29.13
- NRXP 38.54
- Support Level
- SIDU $1.08
- NRXP $2.89
- Resistance Level
- SIDU $2.19
- NRXP $3.15
- Average True Range (ATR)
- SIDU 0.14
- NRXP 0.14
- MACD
- SIDU -0.08
- NRXP -0.04
- Stochastic Oscillator
- SIDU 2.70
- NRXP 10.22
About SIDU Sidus Space Inc.
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.